<DOC>
	<DOCNO>NCT01203917</DOCNO>
	<brief_summary>This study carry see Caucasian patient lung cancer EGFR mutation respond gefitinib ( IRESSA™ ) first line treatment . Safety data also collect analysed confirm treatment gefitinib safe well tolerate .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Gefitinib 1st Line Caucasian Patients With EGFR Mutation Positive Advanced NSCLC</brief_title>
	<detailed_description>An Open Label , Multicentre , Single Arm Study Characterise Efficacy , Safety Tolerability Gefitinib 250 mg ( IRESSA™ ) First line Treatment Caucasian Patients , Epidermal Growth Factor Receptor ( EGFR ) Mutation Positive Locally Advanced Metastatic Non-Small Cell Lung Cancer</detailed_description>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Locally advanced metastatic nonsmall cell lung cancer ( i.e . cancer spread start ) EGFR mutation positive Caucasian female male patient age 18 year Measurable disease , i.e . least one lesion , previously irradiate , ≥ 10 mm long diameter ( ≥ 15 mm short axis lymph node ) Prior adjuvant chemotherapy systemic anticancer treatment le 6 month , palliative radiotherapy le 4 week prior start study treatment . Brain metastases spinal cord compression , unless treat stable without steroid Any clinically significant illness , jeopardize patient ' safety participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Gefitinib</keyword>
	<keyword>EGFR TKI</keyword>
	<keyword>efficacy</keyword>
	<keyword>Caucasian patient</keyword>
	<keyword>EGFR mutation positive advance NSCLC</keyword>
	<keyword>safety</keyword>
</DOC>